Gilead goes all in on its Arcus alliance, paying $725M cash for rights to a slate of cancer drugs. And there's no room for failure
Gilead is going all in — hook, line and sinker — on its oncology alliance with Arcus. And they are going for broke.
The big biotech unveiled a deal that now delivers $725 million in opt-in payments covering the clinical development programs for Arcus, ranging from their closely watched anti-TIGIT programs for domvanalimab and AB308 to etrumadenant (the A2a/A2b adenosine receptor antagonist) and quemliclustat, the small molecule CD73 inhibitor. Gilead will also cover half of the development costs, handing Terry Rosen’s biotech a deal that gives them a clear cash runway to achieving all its goals in oncology.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.